查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425110

心房中膈缺损症市场 – 2024 年至 2029 年预测

Atrial Septal Defect Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年心房中膈缺损症市场规模为24.31亿美元。

心房中膈缺损症（ASD）是最常见的先天性心臟疾病（CHD）之一，也是成人最常见的先天性心臟病。在过去的几十年里，自闭症谱系障碍的治疗方法发生了典范转移。由于经导管治疗方法和器械的发展和完善，器械封堵术治疗自闭症谱系障碍（ASD）已显示出良好的疗效，并且与手术相比，降低了併发症的发生率，因此目前已应用于大多数自闭症谱系治疗方法。的选择在

心房中膈缺损症市场驱动因素

由于患者和医疗保健专业人员越来越偏好微创手术，心房中膈缺损症产业预计将成长。这些创新侵入性较小，可缩短住院时间、加速復原时间并减少疤痕。各种技术进步正在推动产品创新，从而提高病患安全和临床结果。此外，医疗费用的增加和社会对 ASD 治疗意识的提高也是推动心房中膈缺损症市场成长的因素。

中风盛行率增加

中风被认为是全球第二大死因。例如，根据美国疾病管制与预防中心美国的数据，六分之一的心血管疾病死亡病例是中风造成的。在美国，每 40 秒就会发生一次中风，每 3 分 14 秒就会夺走一人生命。美国每年有超过 795,000 人中风。其中约 61 万例为新发或首次中风，约 185,000 例（几乎四分之一）发生在已患过中风的患者中。缺血性中风（即流向大脑的血液受阻）约占所有中风的 87%。这一增长预计将有助于扩大心房中膈缺损症行业的市场占有率。

提高对不同类型心房中膈缺损症的认识

各种心房中膈缺损症的知识的开拓在市场的发展中起着关键作用。当继发孔间隔未完全闭塞继发孔间隔或心房顶原发间隔发生显着吸收时，就会发生继发孔间隔缺损。心房中隔缺损是第三常见的心房中膈缺损症，是由于房间隔无法与心内膜垫连接而引起的。心肌的静脉回流由构成冠状窦的静脉代表，冠状窦是沿着左心房和左心室之间的凹槽运行的动脉。在三尖瓣的隔叶上方，它经常排放右心房的底部。

手术闭合治疗预计将占据最大的市场占有率

手术闭合疗法预计将显着增加，主要是由于其高成功率和长期耐用性。心臟直视手术使用补片或缝合来修復缺损并闭合心臟中的孔。对于患有多种异常或潜在心臟病的患者，建议进行手术闭合。手术闭合被认为是治疗大型复杂自闭症谱系障碍的黄金标准，适合所有年龄层的患者。此外，基于导管的闭合技术预计将占据第二大市场份额。在这种治疗方法中，导管穿过鼠蹊部的小切口进入心臟。

改善医疗团队的成果

房间隔异常患者需要一个由患者小儿科、基层医疗医生和执业护士积极参与的跨专业团队，以改善医疗团队的治疗结果。基层医疗医生通常会在将患者转诊给循环系统之前对 ASD 进行初步诊断。循环系统定期对心房中膈缺损症的成人和儿童进行随访，以检查心臟的解剖结构、功能和血流动力学状态。

在亚太地区，心房中膈缺损症市场预计将稳定成长。

由于先天性心臟疾病率上升以及 ASD 治疗需求不断增长，预计亚太地区的心房中膈缺损症市场将在预测期内增长。推动亚太地区心房中膈缺损症市场成长的主要因素是医疗旅游、医疗基础设施的增加以及医疗保健领域投资的增加。在亚太地区，印度和中国由于人口众多且可支配收入不断增加，预计将占据最大的市场占有率。

政府对心房中膈缺损症市场的监管

  • 美国食品药物管理局(FDA) 透过设备和放射健康中心 (CDRH)监督用于识别和治疗 ASD 的医疗设备。
  • 欧盟 (EU) 根据医疗设备指令 93/42/EEC 对用于 ASD 诊断和治疗的医疗设备进行监管。
  • 世界卫生组织《烟草控制框架公约》(FCTC) 要求各国政府制定法规，减少烟草使用并保护公共卫生免受吸烟的有害影响。

心房中膈缺损症产品

  • Occlutech Figulla Flex II ASD 封堵器，用于 ASD 封堵的第三代 Occlutech 装置，Figulla Flex II ASD 封堵器（FSO，Occlutech GmbH，耶拿，德国）采用柔性钛氧化物涂层镍钛诺网膜和与ASO 相同的双盘。它有一个结构。
  • Nit-Occlud ASD-R，Nit-Occlud ASD-R (NOA-R) 是德国科隆 pfm Medical 製造的双盘、自膨胀、自定心装置；它与其他硝基网膜装置有显着不同。它的特点。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章心房中膈缺损症市场：依症状

  • 介绍
  • 频繁呼吸道感染疾病
  • 腿和脚肿胀
  • 心悸
  • 不适

第六章心房中膈缺损症市场：依诊断分类

  • 介绍
  • 胸部X光检查
  • 心电图

第七章心房中膈缺损症市场：依最终用户分类

  • 介绍
  • 医院
  • 诊所
  • 其他的

第八章心房中膈缺损症市场：依地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Abbott Cardiovascular
  • Lepu Medical Technology Company
  • Gore Medical
  • Mayo Clinic
  • Vaidam
  • Cleveland Clinic
  • Osmosis
  • TriHealth
  • Dorset Heart Clinic
  • The Texas Heart Institute
简介目录
Product Code: KSI061616218

The atrial septal defect market was valued at US$2.431 billion in 2022.

One of the most prevalent congenital heart diseases (CHDs) and the most prevalent CHD in adults is atrial septal defect (ASD). Over the past few decades, the therapy approach for ASD has undergone a paradigm change. Device closure of ASD is currently regarded as the treatment of choice in the majority of patients with secundum ASD, displaying great effectiveness as well as a decreased complication rate compared to surgery, as a consequence of the development and refinement of transcatheter treatment methods and devices.

Driving factors for the atrial septal defect market

The atrial septal defect industry is anticipated to grow due to the rising preference for minimally invasive procedures by patients and healthcare professionals. These innovations are less invasive and offer shorter hospital stays, quicker recuperation times, and minimum scarring. Various technological advancements have led to product innovations that enhance patient safety and clinical outcomes. Moreover, the increasing healthcare costs and growing public awareness of ASD treatments are some other factors fueling the atrial septal defect market growth.

Increasing prevalence of strokes

Stroke is considered the second leading cause of death worldwide. For instance, according to the Centers for Disease Control and Prevention in 2021, stroke was the cause of 1 in 6 fatalities from cardiovascular disease. A stroke occurs in the United States every 40 seconds and claims the life of a person every 3 minutes and 14 seconds. Over 795,000 people in the US experience a stroke each year. Of them, about 610,000 are new or first strokes, and nearly one in four strokes, or around 185,000, occur in persons who have already had a stroke. Ischemic strokes, in which blood flow to the brain is interrupted, account for around 87% of all strokes. This growth will contribute to the growing market share for the atrial septal defect industry.

Rising awareness of different types of atrial septal defects

Growth in knowledge about various atrial septal defects plays a key role in the development of the market. Ostium secundum defect develops when the septum secundum does not completely occlude the ostium secundum or when there is greater reabsorption of the septum primum in the atrium's ceiling. Ostium primum defect is an atrial septal defect, which is the third most frequent, resulting from the septum primum's inability to merge with the endocardial cushions. Heart muscle's venous return is represented by the veins that make up the coronary sinus, an artery that runs along the groove between the left atrium and left ventricle. Above the septal leaflet of the tricuspid valve, it often drains onto the right atrium's floor.

Surgical closure treatment is anticipated to hold the maximum market share

Surgical closure treatment is predicted to rise significantly mainly due to its high success rate and long-term durability. During open-heart surgery, a patch or suture is used to patch up the defect and the hole in the heart is closed. Surgical closures are recommended for patients who have multiple abnormalities or any underlying heart condition. It is regarded as the gold standard for treating large and complex ASDs and is suitable for patients of all ages. Furthermore, catheter-based closures are anticipated to hold the second-largest atrial septal defect market share. This treatment entails a catheter threaded up to the heart through a tiny incision of the groin.

Enhancing healthcare team outcomes

Patients with atrial septal abnormalities require an interprofessional team with significant participation from the patient's paediatrician, primary care doctor, and nurse practitioner to improve healthcare team outcomes. The primary care physician often makes the first diagnosis of ASD before referring the patient to the cardiologist. Cardiologists regularly follow up with patients who have atrial septal defects in adults and children to check on the heart's anatomy, function, and hemodynamic condition.

In Asia Pacific, it is projected that the atrial septal defect market will grow steadily.

The atrial septal defect market is anticipated to grow in Asia Pacific during the projected period due to the rising prevalence of congenital cardiac conditions and the increasing need for ASD therapy. Medical tourism, an increase in healthcare infrastructure, and increased investment in the healthcare sector are the key factors fueling the atrial septal defect market growth in the Asia Pacific region. India and China are anticipated to hold the maximum market share in the Asia Pacific region owing to their vast population and growing disposable income.

Government regulations for the atrial septal defect market

  • Through its Centre for Devices and Radiological Health (CDRH), the Food and Drug Administration (FDA) in the United States oversees medical devices used to identify and treat ASDs.
  • Following the Medical Device Directive 93/42/EEC, the European Union has defined regulations for medical devices used in the diagnosis and treatment of ASDs.
  • Governments are urged by the Framework Convention on Tobacco Control (FCTC) of the WHO to cut back on tobacco use and create regulations to safeguard the public's health from the negative effects of smoking.

Atrial Septal Defect Products

  • Occlutech Figulla Flex II ASD Occluder, The third generation Occlutech device for ASD closure, the Figulla Flex II ASD Occluder (FSO, Occlutech GmbH, Jena, Germany), has a flexible titanium-oxide coated nitinol mesh and a double-disk construction identical to the ASO.
  • Nit-Occlud ASD-R, The Nit-Occlud ASD-R (NOA-R) is a double-disk, self-expandable, self-centering device made by pfm Medical in Cologne, Germany, although it differs significantly from other nitrol-mesh devices in terms of its design features.

Market Key Developments

  • In August 2022, InnAVasc Medical, Inc., a privately held medical technology company, was acquired by W. L. Gore & Associates, Inc. (Gore), a global material science company committed to transforming industries and improving lives.
  • In July 2022, the launch of Qosina's AseptiQuik STC line of Steam-Thru connections was announced. The new line incorporates both the Steam-Thru II Steam-in-Place connector and the AseptiQuik sterile connector, giving manufacturers flexibility between hybrid stainless steel and single-use processing equipment.

Segmentation:

By Symptoms

  • Frequent Respiratory Infections
  • Swelling Legs and Feet
  • Heart Palpitations
  • Fatigue

By Diagnosis

  • Chest X-ray
  • Electrocardiogram

By End-User

  • Hospitals
  • Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ATRIAL SEPTAL DEFECT MARKET, BY SYMPTOMS

  • 5.1. Introduction
  • 5.2. Frequent Respiratory Infections
  • 5.3. Swelling Legs and Feet
  • 5.4. Heart Palpitations
  • 5.5. Fatigue

6. ATRIAL SEPTAL DEFECT MARKET, BY DIAGNOSIS

  • 6.1. Introduction
  • 6.2. Chest X-ray
  • 6.3. Electrocardiogram

7. ATRIAL SEPTAL DEFECT MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. ATRIAL SEPTAL DEFECT MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Abbott Cardiovascular
  • 10.2. Lepu Medical Technology Company
  • 10.3. Gore Medical
  • 10.4. Mayo Clinic
  • 10.5. Vaidam
  • 10.6. Cleveland Clinic
  • 10.7. Osmosis
  • 10.8. TriHealth
  • 10.9. Dorset Heart Clinic
  • 10.10. The Texas Heart Institute